Leptomeningeal disease [clinicaltrials_resource:517899f8386c9fcb756a3fd174d12a6b]
eligibility for clinicaltrials:NCT01567709 [clinicaltrials_resource:054d8f683631bdb2773b86e38105e223]eligibility for clinicaltrials:NCT01460940 [clinicaltrials_resource:3ecd8c0f552ef1a01986cf49e7b89d77]eligibility for clinicaltrials:NCT00041106 [clinicaltrials_resource:6b43d67a0ef8ebcbc7d453df7521ea6f]eligibility for clinicaltrials:NCT00086827 [clinicaltrials_resource:a6bdc66e74bdec3a7869289b534b9ef0]eligibility for clinicaltrials:NCT01413503 [clinicaltrials_resource:a82010c7cac6d6059b2d71cf4e655f04]eligibility for clinicaltrials:NCT01038752 [clinicaltrials_resource:b8d66792377e9a4bcd3b92761f701989]eligibility for clinicaltrials:NCT00469898 [clinicaltrials_resource:fc8a97b7fc5ca15a9f8cc842df76c80f]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT01567709 [clinicaltrials_resource:054d8f683631bdb2773b86e38105e223]eligibility for clinicaltrials:NCT00079235 [clinicaltrials_resource:0a710f5bc928c297442f6b3d4cf6f771]eligibility for clinicaltrials:NCT00040794 [clinicaltrials_resource:13c6f531d9de8a242be6fb95144c97cf]eligibility for clinicaltrials:NCT00006486 [clinicaltrials_resource:2935f863adcde7a18a5f18d6b43c7a31]eligibility for clinicaltrials:NCT00025207 [clinicaltrials_resource:3422071272c4c7fe221cb0aba54b180a]eligibility for clinicaltrials:NCT00601900 [clinicaltrials_resource:36b461d136e65a338c35282e995f5614]eligibility for clinicaltrials:NCT01460940 [clinicaltrials_resource:3ecd8c0f552ef1a01986cf49e7b89d77]eligibility for clinicaltrials:NCT01260688 [clinicaltrials_resource:3f0ebaf7f7cef73daa7b70d582ddfa66]eligibility for clinicaltrials:NCT00470054 [clinicaltrials_resource:447d267c541f5bd31f52aaeb0afbaecc]eligibility for clinicaltrials:NCT00072163 [clinicaltrials_resource:486e53e117286eccc01953ef24c6768c]eligibility for clinicaltrials:NCT00453154 [clinicaltrials_resource:4b000501beb7b60237217dfdd9e04f68]eligibility for clinicaltrials:NCT00134043 [clinicaltrials_resource:4ee031495652de142a93b4905748e504]eligibility for clinicaltrials:NCT00042952 [clinicaltrials_resource:51bacd66798dd95e4640ccb3e6b43beb]eligibility for clinicaltrials:NCT00369655 [clinicaltrials_resource:54be6d2c781973881c050c03266e215a]eligibility for clinicaltrials:NCT00698815 [clinicaltrials_resource:56235a1d38a15d03b2947ac8c60b7497]eligibility for clinicaltrials:NCT00785291 [clinicaltrials_resource:56e8414e7aae4a3cb51827160e7f935f]eligibility for clinicaltrials:NCT00004856 [clinicaltrials_resource:5eee0b578dec07da2d75cb979931f4cf]eligibility for clinicaltrials:NCT00390455 [clinicaltrials_resource:6784055020d150ff3fa09e30c3cc82cd]eligibility for clinicaltrials:NCT00041106 [clinicaltrials_resource:6b43d67a0ef8ebcbc7d453df7521ea6f]eligibility for clinicaltrials:NCT01286272 [clinicaltrials_resource:6d6e6eeb58eeaad063f6bc80559d910a]eligibility for clinicaltrials:NCT00060125 [clinicaltrials_resource:85a3d48d49808d081ae0ca30fa007e31]eligibility for clinicaltrials:NCT00006228 [clinicaltrials_resource:8678da2f44a3087113d5d5816d998565]eligibility for clinicaltrials:NCT00004883 [clinicaltrials_resource:8aeb346dcb893f0a555b1b3b7773666a]eligibility for clinicaltrials:NCT00095693 [clinicaltrials_resource:9f0b394b4ef021767fbf635343907b47]eligibility for clinicaltrials:NCT00086827 [clinicaltrials_resource:a6bdc66e74bdec3a7869289b534b9ef0]eligibility for clinicaltrials:NCT00005949 [clinicaltrials_resource:a806e3facb9192d215c3bfe819a85eef]eligibility for clinicaltrials:NCT01413503 [clinicaltrials_resource:a82010c7cac6d6059b2d71cf4e655f04]eligibility for clinicaltrials:NCT00084461 [clinicaltrials_resource:aabf2d26baa0aec590e96f43f421b227]eligibility for clinicaltrials:NCT00098540 [clinicaltrials_resource:b7e62d0ba12c8983fc51dd566d5f4db0]eligibility for clinicaltrials:NCT00126581 [clinicaltrials_resource:b82241b13eecf2827a7f2a6b75643180]eligibility for clinicaltrials:NCT01038752 [clinicaltrials_resource:b8d66792377e9a4bcd3b92761f701989]eligibility for clinicaltrials:NCT00042978 [clinicaltrials_resource:ce229861efa9c54b2c6abe3c627e44b0]eligibility for clinicaltrials:NCT00693992 [clinicaltrials_resource:df0a935847b1a5cbddd499991e582254]eligibility for clinicaltrials:NCT00112684 [clinicaltrials_resource:e8f0067df901ff3fda1a941a1113bee5]eligibility for clinicaltrials:NCT01229943 [clinicaltrials_resource:ed89dbe114fce9ad74d6fec76acd6dc2]eligibility for clinicaltrials:NCT00469898 [clinicaltrials_resource:fc8a97b7fc5ca15a9f8cc842df76c80f]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Leptomeningeal disease [clinicaltrials_resource:517899f8386c9fcb756a3fd174d12a6b]
Bio2RDF identifier
517899f8386c9fcb756a3fd174d12a6b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:517899f8386c9fcb756a3fd174d12a6b
identifier
clinicaltrials_resource:517899f8386c9fcb756a3fd174d12a6b
title
Leptomeningeal disease
@en
type
label
Leptomeningeal disease [clinicaltrials_resource:517899f8386c9fcb756a3fd174d12a6b]
@en